1GLOBAL
7.5.2024 11:01:34 CEST | Business Wire | Press release
Germany's largest independent mobile service provider, freenet, has partnered with the global telecommunications network 1GLOBAL to power their new offering, freenet Travel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240506185419/en/
1GLOBAL provides roaming services to 7.5 million freenet customers. (Graphic: Business Wire)
This new product creates immediate added value for freenet customers who plan on visiting other countries. Whether travelling for business or leisure, calculating roaming costs and data usage abroad can often be complex. 1GLOBAL eSIMs offer millions of freenet customers a crucial advantage, enabling seamless mobile internet usage in countries outside the EU while avoiding high roaming charges.
"We are among the few providers worldwide capable of supplying and configuring eSIMs ourselves. Through this partnership, millions of freenet customers can now book various data packages for countries outside the EU, allowing them to communicate cost-effectively during their travels."
- Hakan Koç, founder and CEO of 1GLOBAL
1GLOBAL eSIMs: worry-free travel and minimal roaming charges for freenet users
All freenet customers with eSIM-compatible devices now have access to the service. To install the eSIM on their phone, they simply scan a QR code and follow the onscreen prompts. Once downloaded, a 1GLOBAL eSIM can be used as many times as needed in any of the countries supported by the secure high-speed network.
Users can choose from a variety of tariffs and instantly book a data plan for their desired destination, even if they have no internet connection. They will also benefit from 1GLOBAL’s high-speed 4G/5G network. 1GLOBAL has developed a complete eSIM ecosystem including Remote SIM Provisioning (RSP) and Entitlement Servers, ensuring the highest quality throughout the eSIM deployment lifecycle. Their fully integrable API can be customised and adapted to deliver an outstanding client experience across a wide range of telco products.
"By using 1GLOBAL eSIM capabilities, we are embracing a future-proof, modern technology. This enables us to further expand our positioning around digital lifestyle offerings."
- Salome Andrade Pohl, Head of Digital Lifestyle at freenet
About 1GLOBAL
1GLOBAL provides quick and secure mobile network connectivity in over 160 countries worldwide. 1GLOBAL eSIM technology seamlessly integrates into third-party apps and products, and can be installed on any eSIM-compatible mobile device in less than a minute.
Founded in 2022, 1GLOBAL is the new startup of Hakan Koç, co-founder and former co-CEO of AUTO1 Group. 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognised, GSMA-accredited global mobile network. Headquartered in London, with an R&D hub in Lisbon, they have now grown to include over 400 employees across 12 countries and have been granted fully regulated MVNO (mobile virtual network operators) status in nine of them.
About freenet
Freenet offers a comprehensive portfolio of mobile communications, internet, and TV entertainment services. Customers can find the ideal products for their digital life in approximately 500 freenet stores and online at www.freenet-mobilfunk.de.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506185419/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom